Cover Image
市場調查報告書

乳癌單株抗體的全球市場:2016∼2020年

Global Breast Cancer Monoclonal Antibodies Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 370794
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
乳癌單株抗體的全球市場:2016∼2020年 Global Breast Cancer Monoclonal Antibodies Market 2016-2020
出版日期: 2016年09月06日 內容資訊: 英文 88 Pages
簡介

乳癌是乳房組織的細胞惡性化,HER-2乳癌是最常見的類型。HER-2蛋白質出現在正常的乳房組織表面,影響惡性細胞的增生。全球乳癌單株抗體市場,成為預計至2020年達137億美元的收益。

本報告提供全球乳癌單株抗體市場相關調查,市場現狀與成長預測,各地區趨勢,及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 乳癌:概要

  • 這個疾病的理解
  • 乳癌的治療方法
  • 單株抗體概要

第6章 產品研發線

第7章 乳癌單株抗體的全球市場:市場情況

  • 市場概要
  • 波特的五力分析

第8章 乳癌單株抗體的全球市場:各單株抗體類型市場區隔

第9章 乳癌單株抗體的全球市場:各終端用戶市場區隔

  • 醫院
  • 零售藥局

第10章 乳癌單株抗體的全球市場:各地區市場區隔

  • 各地區市場區隔
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 乳癌單株抗體的全球市場:促進要素

第12章 促進要素的影響

第13章 乳癌單株抗體的全球市場:課題

第14章 促進要素與課題的影響

第15章 乳癌單株抗體的全球市場:趨勢

第16章 供應商環境

  • 競爭模式
  • 主要消息
  • Roche
  • Amgen
  • ylan
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

目錄
Product Code: IRTNTR10205

About Breast Cancer mAbs

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

Technavio's analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Roche
  • Mylan

Other Prominent Vendors

  • Array BioPharma
  • AstraZeneca
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Celltrion
  • Chugai Pharmaceutical
  • Daiichi Sankyo
  • DARA Biosciences
  • Eddingpharm
  • Eisai
  • Galena Biopharma
  • GlaxoSmithKline
  • Halozyme Therapeutics
  • Hospira
  • ImmunoGen
  • Immunomedics
  • MacroGenics
  • Merck
  • Novartis
  • Oncothyreon
  • Pfizer
  • ProStrakan
  • Puma Biotechnology
  • Seattle Genetics
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva Pharmaceuticals

Market driver

  • Reimbursement benefits for breast cancer mAbs
  • For a full, detailed list, view our report

Market challenge

  • Absence of adequate diagnosis and screening procedures for early detection
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted and combination therapies for breast cancer
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Breast cancer: Overview

  • Understanding the disease
  • Treatment regimen for breast cancer
  • Overview of mAbs

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by type of mAbs

  • Naked mAbs
  • Conjugated mAbs

PART 09: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 10: Geographical segmentation

  • Global breast cancer mAbs market by geographical segmentation 2015-2020
  • Breast cancer mAbs market in Americas
  • Breast cancer mAbs market in EMEA
  • Breast cancer mAbs market in APAC

PART 11: Market drivers

  • Reimbursement benefits for breast cancer mAbs
  • Increase in demand for breast cancer ADCs
  • Huge market potential for breast cancer mAbs owing to product approvals
  • Exposure to risk factors

PART 12: Impact of drivers

PART 13: Market challenges

  • Absence of adequate diagnosis and screening procedures for early detection
  • High manufacturing costs coupled with stringent regulations
  • Threat from chemotherapy and off-label drugs
  • Difficulties in patient recruitment for conducting clinical trials

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of targeted and combination therapies for breast cancer
  • Growing focus of vendors on untapped markets
  • Emergence of biosimilars
  • Outsourcing of biosimilar manufacturing activities
  • Need for high investment in R&D

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Roche
  • Amgen
  • Mylan
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global breast cancer mAbs market snapshot
  • Exhibit 03: Key buying criteria for breast cancer mAbs 2015
  • Exhibit 04: Impact of key customer segments on market 2015
  • Exhibit 05: Breast cancer stages based on tumor size and extent of metastasis
  • Exhibit 06: Classification of breast cancer based on genetic make-up of tumor cells
  • Exhibit 07: Treatment regimen for breast cancer
  • Exhibit 08: Comparison of small molecules and mAbs
  • Exhibit 09: Preparation of mAbs
  • Exhibit 10: Global breast cancer mAbs market: Key metrics analysis snapshot
  • Exhibit 11: Global breast cancer mAbs market: Pipeline snapshot 2015
  • Exhibit 12: Pipeline portfolio: Global breast cancer mAbs market 2015
  • Exhibit 13: Developmental history of trastuzumab biosimilars in various countries
  • Exhibit 14: Global breast cancer mAbs market snapshot: Developed and emerging markets 2015
  • Exhibit 15: Global breast cancer mAbs market 2015-2020 ($ billions)
  • Exhibit 16: Factors influencing global breast cancer mAbs market 2015
  • Exhibit 17: Timeline for development of breast cancer mAbs
  • Exhibit 18: Impact of drivers and challenges of global breast cancer mAbs market
  • Exhibit 19: Five forces analysis
  • Exhibit 20: Approved naked mAbs by US FDA and EU
  • Exhibit 21: Global breast cancer mAbs market segmentation by type of molecule 2015
  • Exhibit 22: Global breast cancer mAbs market segmentation by end-user 2015
  • Exhibit 23: Global breast cancer mAbs market: Geographical outlook 2015-2020
  • Exhibit 24: Global breast cancer mAbs market: Geographical outlook 2015
  • Exhibit 25: Revenue/growth outlook in different countries/regions 2015
  • Exhibit 26: Global breast cancer mAbs market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 27: Opportunity analysis of breast cancer mAbs market in Americas
  • Exhibit 28: Breast cancer mAbs market in Americas 2015-2020 ($ billions)
  • Exhibit 29: Breast cancer mAbs market in Americas by country 2015
  • Exhibit 30: Opportunity analysis of breast cancer mAbs market in EMEA
  • Exhibit 31: Breast cancer mAbs market in EMEA 2015-2020 ($ billions)
  • Exhibit 32: Opportunity analysis of breast cancer mAbs market in APAC
  • Exhibit 33: Number of individuals treated with Herceptin through patient assistance programs in China 2011-2014
  • Exhibit 34: Breast cancer mAbs market in APAC 2015-2020 ($ billions)
  • Exhibit 35: Global breast cancer mAbs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 36: Impact of drivers
  • Exhibit 37: Five-year survival rate by stage of diagnosis
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Global breast cancer mAbs market: Impact assessment of key trends
  • Exhibit 40: Competitive assessment of vendors
  • Exhibit 41: Key vendors: Geographical presence 2015
  • Exhibit 42: Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
  • Exhibit 43: Roche: Geographical segmentation of Avastin by revenue 2015
  • Exhibit 44: Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
  • Exhibit 45: Roche: Geographical segmentation of Herceptin 2015
  • Exhibit 46: Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
  • Exhibit 47: Roche: Geographical segmentation of Perjeta 2015
  • Exhibit 48: Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
  • Exhibit 49: Roche: Geographical segmentation of Kadcyla 2015
  • Exhibit 50: Roche: Metrics analysis
  • Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
  • Exhibit 52: Amgen: Geographical segmentation of Xgeva 2015
  • Exhibit 53: Amgen: Metrics analysis
  • Exhibit 54: Mylan: Business segmentation by revenue 2015
  • Exhibit 55: Mylan: Geographical segmentation by revenue 2015 (generics segment)
  • Exhibit 56: Mylan: Metrics analysis
Back to Top